Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

The CDC advisory committee also endorsed GSK's pentavalent meningococcal vaccine.

Panelists discuss how choosing topical treatments requires individualized therapy considering factors such as affected body areas, disease severity, patient age, formulation preferences, and insurance coverage.

Panelists discuss how roflumilast demonstrated good efficacy with 56% to 57% of patients achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 after long-term use, making it effective for maintenance therapy with good tolerability.

Panelists discuss how newer nonsteroidal topical treatments like phosphodiesterase-4 inhibitors (crisaborole and roflumilast), JAK inhibitors (ruxolitinib), and aryl hydrocarbon receptor agonists (tapinarof) are expanding options for atopic dermatitis treatment.

Panelists discuss how long-term use of topical steroids is prevalent with 50% of patients using them 15 to 30 days per month, leading to concerns about adverse effects, including topical steroid withdrawal syndrome.